pancreat
cancer
lead
caus
cancer
death
unit
state
lowest
surviv
rate
solid
tumor
larg
owe
fact
radiat
surgeri
current
chemotherapi
option
ineffect
new
treatment
strategi
essenti
human
mesothelin
normal
express
mesotheli
cell
pleura
peritoneum
pericardium
howev
mesothelin
overexpress
high
percentag
ovarian
cancer
pancreat
cancer
lung
cancer
mesothelioma
make
potenti
target
anticanc
treatment
human
mous
mesothelin
share
sequenc
similar
express
pattern
biochem
characterist
homeostat
function
mesothelin
mammal
unknown
gene
delet
without
appar
effect
mice
human
mesothelin
propos
malign
factor
increas
tumor
cell
prolifer
migrat
vitro
tumor
size
nude
mice
sirna
specif
mesothelin
suppress
tumor
growth
rat
renal
carcinoma
model
howev
shown
stabl
overexpress
mesothelin
pancreat
cancer
cell
line
increas
cell
prolifer
anchorag
independ
growth
vitro
suggest
mesothelin
necessarili
tumor
progress
factor
inde
test
effect
mesothelin
express
presenc
intact
host
immun
system
found
overexpress
mesothelin
unexpectedli
decreas
metastas
even
inhibit
tumor
format
vivo
immunocompet
mice
suggest
immun
respons
mesothelin
might
effect
reduc
tumor
growth
tumor
associ
antigen
interest
target
express
cancer
cell
normal
adult
tissu
number
studi
includ
phase
ii
clinic
trial
ongo
target
mesothelin
express
cancer
chimer
antibodi
immunotoxin
drug
conjug
bind
mesothelin
test
well
chimer
antigen
receptor
tcell
car
cell
bind
kill
mesothelinexpress
cell
live
attenu
listeria
monocytogenesexpress
mesothelin
evalu
anticanc
vaccin
antibodi
lymphocyt
shown
protect
antimesothelin
activ
fact
may
especi
use
irradi
tumor
cell
enhanc
express
mesothelin
antimesothelin
vaccin
may
effect
combin
irradi
wellcharacter
recombin
immunotoxin
mesothelin
monoclon
antibodi
phase
studi
given
bolu
iv
infus
patient
mesothelinexpress
pancreat
cancer
publish
show
safeti
feasibl
unfortun
clinic
respons
addit
high
affin
monoclon
antibodi
develop
bind
altern
region
mesothelin
protein
allow
addit
mesothelin
target
presenc
sever
poxvirus
use
recombin
vector
develop
vaccin
wide
rang
infecti
diseas
includ
bacteri
viral
parasit
pathogen
well
cancer
therapi
sever
approv
current
clinic
trial
hiv
vaccin
demonstr
efficaci
human
date
employ
avian
poxviru
vector
enter
nihsponsor
phase
trial
poxvirus
vaccinia
viru
suitabl
vector
easili
grown
high
titer
wide
varieti
anim
cell
type
accommod
insert
larg
piec
dna
genom
stabl
even
dri
induc
robust
b
cell
immun
vaccinia
viru
commonli
use
poxviru
vaccin
vector
howev
use
limit
potenti
virul
especi
immunocompromis
host
raccoonpox
viru
provid
safer
vector
compar
vaccinia
viru
modifi
vaccinia
viru
ankara
mva
strain
even
attenu
replic
mammalian
cell
howev
mva
immunogen
limit
requir
high
dose
boost
vaccin
poxvirus
shown
efficaci
vaccin
platform
cancer
patient
respons
still
need
improv
order
strengthen
immun
respons
treatment
outcom
develop
recombin
mva
miss
immunosuppress
virul
gene
block
antigen
present
b
lymphocyt
respons
remov
gene
improv
antibodi
cytokin
product
number
respond
lymphocyt
immunoglobulin
class
switch
current
studi
assess
safeti
immunogen
protect
efficaci
therapeut
mva
viru
vaccin
express
mesothelin
mvameso
heterotop
pancreat
tumor
model
use
pancreat
adenocarcinoma
cell
line
express
mesothelin
cultur
tumor
mous
model
tumor
line
deriv
mice
thu
grown
syngen
mice
allow
studi
antitumor
immun
respons
immunocompet
mous
model
great
advantag
tumor
studi
perform
xeno
allograft
immunocompromis
mice
determin
whether
improv
vaccin
immunogen
efficaci
test
parent
normal
mvameso
viru
vaccin
mva
mesothelin
express
viru
immunosuppress
gene
remov
chemicallyinduc
pancreat
adenocarcinoma
cell
line
kind
gift
dr
kepe
xie
md
anderson
cancer
center
houston
tx
cell
grown
rpmi
fetal
bovin
serum
mm
glutamin
uml
penicillin
streptomycin
mesothelin
express
cell
line
describ
zervo
et
al
cell
incub
vaccinia
viru
mva
mva
delet
mutant
virus
previous
describ
babi
hamster
kidney
bhk
cell
employ
growth
mva
cultur
use
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
mm
glutamin
uml
penicillin
streptomycin
order
creat
therapeut
antimesothelin
vaccin
insert
mous
mesothelin
mva
viral
genom
use
normal
wild
type
mva
mva
virul
gene
delet
creat
mvameso
viru
recombin
virus
respect
case
mesothelin
clone
vector
gift
l
wyatt
nation
institut
health
design
insert
area
mva
genom
gene
natur
delet
passag
viru
recombin
virus
express
gfp
marker
protein
select
purifi
analyz
confirm
genotyp
raid
prep
pcr
analysi
presenc
mesothelin
gene
confirm
use
mesothelinspecif
primer
ggctggctatggctgtaagac
agcagtgttggatgagtccatcgt
anneal
temperatur
c
order
assess
presenc
gene
recombin
virus
analyz
use
specif
primer
tgactataacagatacatt
cagattatctgaaggattgat
anneal
temperatur
c
confirm
insert
site
mesothelin
use
primer
mva
flank
region
cataagtataaagtccgactattgttc
gataaagttgcatcatcacctat
pcr
amplicon
run
agaros
gel
peptid
repres
murin
mesothelin
code
sequenc
gvygfqvseadvralgglac
cppgkepykvdedlifyqn
synthes
conjug
klh
carrier
protein
via
termin
cystein
residu
underlin
genem
synthesi
use
immun
two
rabbit
sera
confirm
reactiv
immun
peptid
elisa
bhk
cell
uninfect
infect
mva
virus
multipl
infect
moi
plaqu
form
unit
pfu
infecti
viru
particl
viru
per
cell
h
atmospher
cell
lyse
disrupt
buffer
heat
inactiv
five
minut
dna
sheer
use
needl
sampl
load
onto
precast
gradient
gel
thermo
scientif
sdspage
transfer
overnight
membran
block
minut
room
temperatur
fat
free
milk
tb
incub
rabbit
antimesothelin
antibodi
h
room
temperatur
wash
incub
antirabbit
igg
fc
ap
conjug
promega
room
temperatur
one
h
wash
develop
western
blue
stabil
substrat
promega
hek
transect
cell
previous
describ
use
control
analysi
releas
mesothelin
supernat
collect
well
contain
normal
mesothelin
overexpress
cell
uninfect
bhk
cell
cell
infect
mva
virus
cell
supernat
run
sdspage
gel
transfer
pvdf
membran
probe
rabbit
antimesothelin
antibodi
alkalin
phosphatas
conjug
antibodi
describ
femal
mice
charl
river
week
age
use
experi
mice
hous
east
carolina
univers
depart
compar
medicin
aaalac
accredit
anim
facil
kept
convent
condit
full
access
food
water
throughout
studi
procedur
approv
institut
anim
care
use
committe
accord
recommend
proper
care
use
laboratori
anim
order
assess
safeti
inject
mva
viru
express
mesothelin
inject
mice
im
n
pb
normal
wild
type
mva
mvameso
x
pfumous
im
ul
boost
month
later
x
pfumous
monitor
mous
health
daili
bodi
score
condit
weight
day
similar
previou
work
number
gamma
interferon
ifngamma
secret
spleen
cell
enumer
similarli
method
describ
previous
ninetysixwel
plate
immulon
thermo
electron
coat
overnight
purifi
rat
antimous
ifngamma
mgml
pharmingen
plate
wash
block
buffer
ad
titrat
murin
splenocyt
rpmi
medium
splenocyt
harvest
pb
mva
mvameso
infect
mice
month
vaccin
vitro
stimul
splenocyt
achiev
either
addit
cell
wild
type
vaccinia
viru
moi
lewi
lung
cell
express
mous
mesothelin
follow
incub
h
plate
wash
pb
tween
sodium
azid
incub
biotinyl
rat
antimous
ifngamma
mgml
pharmingen
h
plate
wash
incub
streptavidinap
h
plate
develop
agarosebcip
indolylphosph
amp
mixtur
spot
count
use
dissect
microscop
assess
viral
replic
time
cell
plate
plate
bhk
cell
use
posit
control
sinc
mva
known
replic
bhk
cell
infect
mva
moi
pfucel
h
inocula
remov
cell
wash
supernat
cell
harvest
separ
six
time
point
h
postinfect
sampl
frozen
thaw
three
time
titer
bhk
cell
plate
cell
cellswel
plate
triplic
plate
mva
ad
well
multipl
infect
moi
pfucel
h
ul
inner
saltphenazin
methosulph
mtspm
mgml
mt
promega
mgml
pm
sigma
ad
well
absorb
read
nm
media
use
defin
background
control
level
use
syngen
heterotop
tumor
model
employ
murin
pancreat
adenocarcinoma
cell
line
femal
mice
charl
river
week
age
n
per
group
inject
sc
right
flank
cell
one
inject
per
mous
isofluran
inhal
anesthesia
tumor
size
measur
three
time
per
week
digit
calip
volum
calcul
smallest
x
largest
diamet
mice
human
euthan
reach
endpoint
bodi
condit
score
tumor
size
ulcer
impair
analysi
safeti
immunogen
mice
inject
x
pfumous
im
ul
boost
month
later
x
pfumous
treatment
tumor
bear
mice
mice
inject
sc
right
flank
cell
inject
im
contralater
x
pfumous
ul
time
day
tumor
cell
inject
prevaccin
mice
mice
inject
im
x
pfumous
boost
x
pfumous
challeng
tumor
cell
viral
inject
tumor
tumor
allow
grow
viral
inject
x
pfumous
ul
tumor
began
tumor
experi
repeat
least
three
time
repres
data
shown
twotail
student
test
use
compar
group
p
valu
consid
signific
tumor
associ
antigen
mesothelin
often
induc
robust
immun
respons
evid
suggest
possibl
gener
antitumor
respons
present
tumor
antigen
immunogen
context
express
protein
viral
infect
order
creat
put
therapeut
antimesothelin
vaccin
insert
mous
mesothelin
gene
poxviru
mva
genom
viral
promot
mesothelin
would
express
cell
infect
recombin
viru
construct
normal
wild
type
mva
viru
express
mesothelin
mvameso
mesothelinexpress
mva
viru
viral
immunosuppress
virul
gene
delet
purifi
virus
analyz
pcr
confirm
presenc
mesothelin
gene
expect
loci
genom
presenc
absenc
gene
next
want
confirm
express
mesothelin
protein
recombin
viral
genom
infect
cell
shown
fig
mesothelin
protein
detect
broad
band
kda
mesothelin
glycosyl
differ
glycosyl
seen
differ
mw
band
glycosyl
form
may
vari
differ
cell
type
mesothelin
protein
strongli
express
mva
mesothelin
virusinfect
bhk
cell
monom
appar
dimer
kda
cell
infect
mva
parent
wild
type
viru
uninfect
bhk
cell
fig
indic
recombin
mesothelin
express
virus
abl
express
signific
quantiti
mesothelin
protein
infect
cell
control
mesothelin
detect
western
blot
hek
cell
transfect
mesothelin
express
plasmid
strong
promot
hek
cell
transfect
control
plasmid
vector
mesothelin
could
also
detect
murin
pancreat
adenocarcinoma
cell
line
shown
previous
western
blot
flow
cytometri
mesothelin
tumor
associ
antigen
detect
cell
grown
vitro
tumor
grown
mous
highli
abund
protein
multipl
form
size
cleav
mesothelin
protein
report
releas
cell
express
previous
shown
form
mesothelin
protein
found
supernat
cell
carboxi
termin
region
releas
furin
cleavag
one
deriv
amino
terminu
assess
form
mesothelin
protein
present
supernat
bhk
cell
infect
mva
virus
wild
type
mva
mvameso
comparison
cultur
cell
overexpress
mesothelin
seen
fig
sever
protein
band
react
rabbit
anti
mesothelin
antisera
detect
western
blot
larg
quantiti
releas
mesothelin
appar
cell
infect
recombin
virus
encod
mesothelin
order
assess
safeti
inject
mva
virus
express
mesothelin
inject
mice
im
n
pb
wild
type
mva
mvameso
mice
boost
month
later
monitor
mous
health
bodi
score
condit
daili
weight
day
shown
fig
signific
differ
group
observ
advers
effect
vaccin
suggest
signific
antimesothelin
autoimmun
diseas
induc
mice
determin
whether
virus
express
mesothelin
protein
abl
induc
immun
respons
mice
first
attempt
measur
antimesothelin
antibodi
vaccin
mous
sera
attempt
measur
reactiv
cell
express
mesothelin
surfac
flow
cytometri
done
previous
howev
got
low
respons
possibl
due
releas
mesothelin
fig
bind
anti
mesothelin
antibodi
vivo
measur
frequenc
antimesothelin
ifngamma
secret
lymphocyt
elispot
assay
mice
vaccin
pb
mva
splenocyt
secret
ifngamma
respons
cell
fig
mvameso
vaccin
mice
averag
ifngamma
secret
cell
per
splenocyt
averag
significantli
p
mva
pb
treat
mice
comparison
spot
respons
stimul
lewi
lung
cell
express
mous
mesothelin
mice
vaccin
mva
mvameso
virus
good
respons
restimul
vaccinia
viru
spot
respect
result
indic
mice
respond
viru
infect
mesothelin
express
virus
induc
immun
respons
mice
reactiv
respons
mesothelin
express
cell
addit
vaccin
viru
induc
respond
lymphocyt
compar
mvameso
viru
suggest
remov
induc
stronger
immun
respons
differ
reach
statist
signific
oncolyt
poxvirus
shown
specif
target
replic
tumor
tissu
vivo
tumor
microenviron
support
viral
replic
therefor
want
assess
mva
viru
abl
infect
replic
cell
onestep
viral
growth
curv
mva
unabl
replic
almost
mammalian
cell
babi
hamster
kidney
bhk
cell
one
known
except
mva
replic
bhk
cell
infect
moi
pfucel
cell
would
infect
supernat
cell
harvest
separ
titer
viru
quantiti
time
shown
fig
h
number
infecti
mva
virion
plaqu
form
unit
pfu
increas
bhk
cell
log
mva
replic
cell
also
increas
log
suggest
mva
virus
might
effect
oncolyt
virus
vivo
sinc
infect
replic
select
tumor
cell
unabl
replic
normal
mammalian
tissu
virus
releas
supernat
also
increas
mva
infect
cell
line
result
promis
indic
viru
could
potenti
amplifi
situ
spread
cell
initi
infect
time
viru
inocul
sinc
mva
abl
replic
cell
want
assess
whether
mva
abl
kill
cell
vitro
cell
uninfect
infect
moi
pfucel
compar
media
cell
infect
allow
proceed
h
mt
reagent
ad
measur
cell
metabol
measur
viabil
fig
show
increas
amount
viru
decreas
viabil
cell
similar
result
found
infect
cell
mvameso
virus
result
indic
mva
infect
cell
replic
kill
test
hypothesi
administr
mesothelin
express
virus
could
induc
immun
respons
reduc
mesothelin
express
tumor
growth
establish
tumor
mice
treat
mva
mesothelin
virus
test
remov
immunosuppress
gene
improv
therapeut
vaccin
efficaci
assess
mvameso
viru
compar
viru
tumor
establish
sc
inject
tumor
one
flank
mice
day
post
tumor
inject
mice
inject
im
contralater
ul
pb
mva
mvameso
virus
fig
show
tumor
grew
similarli
regardless
viru
treatment
surviv
b
improv
previous
describ
construct
stabl
mesothelin
express
cell
shown
tumor
form
cell
significantli
smaller
tumor
express
wild
type
level
mesothelin
also
test
whether
mesothelin
express
virus
might
greater
efficaci
cell
express
higher
level
target
howev
also
efficaci
tumor
cell
express
increas
level
protein
tumor
continu
grow
rapidli
sinc
tumor
grow
rapidli
test
whether
induc
immun
respons
mesothelin
prior
tumor
induct
would
protect
tumor
growth
mice
inject
im
pb
wild
type
mva
mvameso
boost
week
later
two
week
boost
tumor
cell
inject
sc
contralater
flank
shown
fig
prior
vaccin
mvameso
significantli
decreas
tumor
growth
increas
surviv
time
next
attempt
direct
intratumor
inject
sinc
mva
abl
replic
kill
cell
vitro
inject
tumor
cell
sc
tumor
reach
inject
pb
wild
type
mva
mvameso
directli
tumor
time
day
apart
howev
unabl
detect
benefit
fig
also
attempt
treat
stabl
mesothelin
overexpress
tumor
intratumor
inject
howev
appar
effect
tumor
continu
grow
mice
euthan
shown
murin
mesothelin
express
mva
viru
genom
detect
kda
monom
protein
sdspage
immunoblot
kda
presum
dimer
mesothelin
releas
cell
detect
supernat
cultur
cell
much
higher
quantiti
cell
infect
mva
virus
express
mesothelin
viral
promot
inject
mesothelin
express
virus
anim
caus
appar
ill
effect
least
month
vaccin
suggest
mvameso
vaccin
safe
initi
deleteri
autoimmun
respons
mvameso
vaccin
induc
strong
respons
mesothelin
express
tumor
cell
line
slightli
smaller
amount
antivaccinia
viru
lymphocyt
induc
inject
vaccinia
viru
result
indic
mesothelin
protein
express
immunogen
form
viru
infect
mice
furthermor
mva
viru
without
mesothelin
express
abl
replic
kill
tumor
cell
grown
vitro
suggest
would
effect
oncolyt
viru
vivo
previou
result
suggest
mesothelin
might
good
target
control
immun
respons
mesothelin
overexpress
reliabl
caus
decreas
heterotop
tumor
growth
immunocompet
syngen
mous
model
vitro
prolifer
inhibit
togeth
result
suggest
mvameso
might
effect
treatment
tumor
might
effect
given
improv
immunogen
properti
howev
unabl
demonstr
efficaci
mesothelin
mva
vaccin
prophylact
therapeut
even
multipl
boost
inject
directli
tumor
one
possibl
tumor
cell
line
simpli
aggress
control
anim
model
tumor
microenviron
may
act
protect
promot
tumor
cell
growth
hope
intratumor
inject
would
allow
viru
replic
spread
kill
tumor
cell
see
potent
oncolyt
effect
anim
perhap
mva
viru
kill
tumor
cell
vitro
antivir
immun
respons
vivo
limit
replic
spread
viru
ineffect
antitumor
immun
respons
may
also
caus
shed
mesothelin
tumor
vivo
decoy
mesothelin
block
immun
effector
antibodi
cell
mesothelin
known
detect
supernat
cell
sera
patient
mesothelin
express
tumor
shed
solubl
mesothelin
may
taken
cell
bind
antimesothelin
antibodi
render
ineffect
problem
may
worsen
administr
mesothelinexpress
virus
also
releas
solubl
mesothelin
high
level
anoth
possibl
shed
mesothelin
induc
state
anergytoler
anim
data
show
mesothelin
specif
lymphocyt
gener
anim
even
though
solubl
circul
mesothelin
shed
mesothelin
viru
infect
cell
perhap
new
develop
cart
cell
may
abl
effect
facilit
cell
target
kill
cancer
cell
data
show
mvameso
vaccin
abl
gener
lymphocyt
respons
activ
cell
induc
stronger
respons
howev
may
possibl
cell
develop
mutat
protect
effect
cytotox
lymphocyt
kill
even
lymphocyt
appropri
expand
target
recogn
tumor
develop
human
anim
alreadi
highli
select
vivo
avoid
immun
respons
control
cancer
improv
oncolyt
therapeut
vaccin
may
made
includ
cytokin
gmcsf
report
improv
oncolyt
potenti
vaccinia
viru
ultim
host
surviv
addit
deplet
regulatori
cell
may
counteract
homeostat
cancer
cell
driven
immunosuppress
enhanc
develop
mesothelinspecif
cell
capabl
kill
tumor
cell
although
result
suggest
immun
respons
counterproduct
anti
mesothelin
immun
respons
may
induc
autoantibodi
target
antigen
well
protein
epitop
spread
antigenspread
autoantibodi
may
caus
increas
damag
anim
previous
shown
antigen
spread
associ
trend
toward
decreas
surviv
patient
prostat
cancer
treat
recombin
viral
vaccin
final
given
difficulti
target
antigen
like
mesothelin
shed
may
effect
target
antigen
shed
recent
result
target
differ
pancreat
tumor
associ
antigen
oncofet
fucoserich
glycovari
patholog
bile
saltdepend
lipas
suggest
may
superior
tumor
target
antigen
